HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

Core Viewpoint - HeartSciences Inc. is leveraging AI technology to enhance ECG diagnostics, aiming to improve early detection of heart disease and save lives [1][3]. Group 1: Company Overview - HeartSciences is focused on transforming ECGs/EKGs through AI to enhance their clinical utility, particularly in frontline clinical settings [3]. - The company possesses one of the largest libraries of AI-ECG algorithms and plans to offer these algorithms via a cloud-based solution and a low-cost ECG hardware platform [3]. - The first product candidate, MyoVista® wavECG™, is a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, traditionally available only through cardiac imaging [3]. Group 2: Market Opportunity - The AI-ECG platform is designed to significantly improve the diagnostic capabilities of standard ECGs, enabling faster and earlier detection of heart disease at the point of care [2]. - The upcoming investor webinar on May 14, 2025, will provide insights into HeartSciences' mission and market opportunities, along with a discussion on the current Regulation A investment opportunity [2]. Group 3: Investment Information - HeartSciences is offering securities under Tier II of Regulation A, providing qualified investors access to investment opportunities typically unavailable in public markets [2][5].